P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T...

por Facon, T., Kumar, S. K., Plesner, T., Moreau, P., Bahlis, N., Goldschmidt, H., O’Dwyer, M., Perrot, A., Venner, C. P., Weisel, K., Mace, J. R., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Borgsten, F., Usmani, S. Z.
Publicado 2022

P891: IXAZOMIB, POMALIDOMIDE AND DEXAMETHASONE (IXPD) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) CHARACTERIZED WITH HIGH-RISK CYTOGENETICS. IFM 2014-01

por Bobin, A., Manier, S., De Keizer, J., Karlin, L., Perrot, A., Hulin, C., Caillot, D., Mariette, C., Lenain, P., Richez, V., Tiab, M., Touzeau, C., Jaccard, A., Decaux, O., Araujo, C., Belhadj, K., Benboubker, L., Déal, C., Macro, M., Vincent, L., Arnulf, B., Bareau, B., Braun, T., Calmettes, C., mamoun, D., Zerazhi, H., Demarquette, H., Feugier, P., Fohrer-sonntag, C., Godet, S., Petillon, M.-O., Avet-Loiseau, H., Leleu, X.
Publicado 2022